Clinical Trials
25 trialsSURGIGAST
University Hospital, Lille
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
RECAP
Swiss Cancer Institute
Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases
Wake Forest University Health Sciences
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
UNC Lineberger Comprehensive Cancer Center
Organ-sparing With TraceITĀ® for Rectal Cancer Radiotherapy
University Hospital, Geneva
NEOPA
UniversitƤtsklinikum Hamburg-Eppendorf
Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers
NYU Langone Health
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
NYU Langone Health
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Alliance for Clinical Trials in Oncology
BOS2
European Organisation for Research and Treatment of Cancer - EORTC
Evaluation of Patients With Bulky GIST Using Sunitinib
University of Alabama at Birmingham
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
Hoosier Cancer Research Network
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
CHIP
Centre Hospitalier Universitaire de Nice
GTX-RT in Borderline Resectable Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Net-Pac
CHIR-Net
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer
Southwestern Regional Medical Center
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
University of Rochester
PGC
Vrinnevi Hospital
Radiation Therapy With Capecitabine in Rectal Cancer
University of Michigan Rogel Cancer Center